Full-Time

Publishing Manager

Regulatory Affairs

Posted on 4/23/2025

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

No salary listed

Senior, Expert

Cambridge, MA, USA

Expected to be in office 70% of the time with flexibility to work from home up to 30%.

Category
Legal
Risk & Compliance
Legal & Compliance
Requirements
  • Bachelor’s degree or equivalent.
  • At least 5 years of experience as a regulatory Publisher in a pharmaceutical company or CRO, with 2+ years in a management role.
  • Experience leading the submission of MAA, INDs, NDAs, BLAs, Master Files, etc., formatted according to international eCTD requirements.
  • Clinical report and global submission dossier publishing/compilation experience in the pharmaceutical or related industry.
  • Experience with electronic clinical document publishing standards/formats and global regulatory submission publishing standards/formats (e.g., eCTD, EU CTR).
  • Working knowledge of publishing tools (e.g., DXC, eCTD Xpress, Veeva), global submission validation tools, Document Management systems, Toolbox, HA electronic submission gateways, IRIS, CTIS, MS Office tools.
  • Familiarity with global Clinical and Regulatory HA requirements (e.g., FDA, ICH, EMA, MENA region, CH, MHRA).
  • Strong interpersonal and project management skills, with experience working in a complex, global cross-functional organization.
  • Highly motivated, organized, and detail-oriented team player.
  • Analytical thinker with excellent problem-solving skills and the ability to adapt to changing priorities and deadlines.
  • Ability to readily adjust to change in a fast-paced environment and multitask.
  • Positive attitude and ability to effectively collaborate with peers, stakeholders, and cross-functional colleagues in a global team environment.
  • Strong technical skills.
  • Strong communication and business writing skills.
  • Fluency in English.
Responsibilities
  • Compile, publish, and verify submission dossiers in accordance with international eCTD requirements.
  • Act as a team leader, providing direction, support, and mentorship to the publishing team.
  • Oversee the compilation, publishing, and verification of submission dossiers in accordance with international eCTD requirements and regulatory guidelines.
  • Lead and manage the submission of MAA, INDs, NDAs, BLAs, Master Files, and other regulatory documents.
  • Work closely with team members to compile documents, review hypertext links, ensure PDFs are submission ready, format tables and graphics, bookmark sections, and proof submissions according to internal standards.
  • Develop and implement new processes and procedures to enhance efficiency and accuracy during the submission process.
  • Collaborate with submissions management to build technically valid and high-quality dossiers.
  • Manage the submission of eCTD sequences through health authority gateways.
  • Perform quality control (QC) of documents published by team members to ensure compliance with applicable guidance documents.
  • Assist with the remediation of Word documents to ensure proper format and compliance.
  • Mentor and train team members to increase the quality across the team.
  • Participate in internal and external audits, maintaining compliance with department systems, e.g., project database, timesheets, training.
  • Contribute to the development of new publishing services and actively participate in department initiatives and process improvements.
  • Maintain a strong understanding of applicable regulatory guidelines and ensure the achievement of individual and team utilization targets.
  • Act as the primary point of contact for the team, providing regular updates to senior management on project status and any issues affecting quality, timelines, and adherence to contractual obligations.
Desired Qualifications
  • Strong interpersonal skills.
  • Ability to adapt to a fast-paced environment.
  • Positive attitude and ability to effectively collaborate with peers, stakeholders, and cross-functional colleagues in a global team environment.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treating diseases. Unlike traditional methods that often rely on proteins or viruses, Moderna's mRNA technology allows for a more flexible and efficient way to develop and manufacture drugs. The company's goal is to harness the power of mRNA to improve patient outcomes and transform the landscape of medicine.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's mRESVIA vaccine approved in Australia and UK for RSV prevention in older adults.
  • The biomanufacturing training program with Bioversity and MCPHS enhances workforce skills.
  • Moderna's next-gen COVID and flu/COVID vaccines diversify its product portfolio.

What critics are saying

  • Moderna faces a bribery scandal related to COVID-19 vaccine trials.
  • The patent lawsuit with Pfizer and BioNTech could lead to financial liabilities.
  • Moderna reported a net loss of $3.6 billion in 2024, raising financial stability concerns.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for new categories of medicines.
  • The company focuses on mRNA vaccines beyond COVID-19, like RSV and flu/COVID combo.
  • Moderna collaborates with Merck on a personalized cancer vaccine, launching in 2027.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

5%
Slay News
Apr 27th, 2025
Moderna Faces Ban for Bribing Children to Join Covid 'Vaccine' Trials

Moderna could face suspension over the practices deemed "unacceptable" by regulators.

Notas de Prensa
Apr 7th, 2025
Moderna to showcase its extensive research on Infectious Diseases at ESCMID 2025.

Moderna, Inc. (NASDAQ:MRNA) announces that it will present at the World Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), which will be held in Vienna, Austria, from April 11 to 15, 2025, its research in multiple areas of infectious diseases, such as COVID-19, influenza, respiratory syncytial virus, cytomegalovirus, norovirus, and mpox.

PharmiWeb
Mar 31st, 2025
Moderna Receives Australian Therapeutic Goods Administration Approval For Rsv Vaccine For Older Adults

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older.1 mRESVIA's approval marks a significant milestone as it is the first mRNA vaccine in Australia approved for use against a disease beyond COVID-19."We are pleased to receive regulatory approval for mRESVIA in Australia following the TGA's decision," said Stéphane Bancel, Chief Executive Officer of Moderna. "This approval underscores our commitment to protecting older adults from RSV-related respiratory diseases. We look forward to supplying mRESVIA from our Melbourne facility to older Australians vulnerable to RSV in the future."RSV is a highly contagious respiratory virus that causes a substantial burden of disease, particularly in older adults. In the 2024 Australian winter period, RSV laboratory-notified cases in adults aged 65 and older were nearly two-thirds the number of influenza cases in the same age group.2 90% of RSV-related deaths reported nationally occurred in those aged 60 years and older, underscoring its potential for severe impact on older Australians.2The approval is based on positive data from the Phase 3 clinical trial ConquerRSV, a randomized, placebo-controlled, observer-blind, case-driven clinical study conducted in approximately 37,000 adults aged 60 years or older in 22 countries.About mRESVIA (Respiratory Syncytial Virus Vaccine)mRNA-1345 is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells

PharmiWeb
Mar 28th, 2025
Moderna Receives Medicines And Healthcare Products Regulatory Agency Marketing Authorization In The Uk For Rsv Vaccine

mRESVIA® is Moderna's second approved product in the UKCAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older."The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna. "Our RSV vaccine will be manufactured at the Moderna Innovation and Technology Centre in Oxfordshire, which will be fully operational later this year."RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia. In the UK, RSV has an impact on elderly adults and is responsible for 175,000 GP appointments, 14,000 hospitalizations, and 8,000 deaths in adults 65 years of age and older per year.[i]"Given the serious consequences of RSV for older people, which can lead to hospitalization and severe outcomes, we are delighted that the MHRA has authorized our RSV vaccine," said Darius Hughes, UK General Manager of Moderna. "With the MHRA decision, mRESVIA becomes Moderna's second approved product in the UK, further demonstrating the role of mRNA vaccines in helping to protect the public from respiratory diseases."The approval is based on positive data from the Phase 3 clinical trial ConquerRSV , a randomized, placebo-controlled, observer-blind, case-driven clinical study conducted in approximately 37,000 adults aged 60 years or older in 22 countries. No serious safety concerns were identified in the Phase 3 trial.About mRNA-1345 (Respiratory Syncytial Virus Vaccine)mRNA-1345 is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein

Bioversity International
Mar 27th, 2025
Bioversity and the Massachusetts College of Pharmacy and Health Sciences (MCPHS) Launch New Biomanufacturing Training Program in Collaboration with Moderna

Bioversity and the Massachusetts College of Pharmacy and Health Sciences (MCPHS) launch new biomanufacturing training program in collaboration with Moderna.

INACTIVE